Related Experiment Video
Updated: May 16, 2026

A High-content In Vitro Pancreatic Islet β-cell Replication Discovery Platform
Published on: July 16, 2016
Trefoil factor 2 promotes cell proliferation in pancreatic β-cells through CXCR-4-mediated ERK1/2 phosphorylation
Kazuki Orime1, Jun Shirakawa, Yu Togashi
1Department of Endocrinology and Metabolism, Graduate School of Medicine, Yokohama-City University, 3-9 Fuku-ura, Kanazawa-ku, Yokohama 236-0004, Japan.
Abstract:
Decreased β-cell mass is a hallmark of type 2 diabetes, and therapeutic approaches to increase the pancreatic β-cell mass have been expected. In recent years, gastrointestinal incretin peptides have been shown to exert a cell-proliferative effect in pancreatic β-cells. Trefoil factor 2 (TFF2), which is predominantly expressed in the surface epithelium of the stomach, plays a role in antiapoptosis, migration, and proliferation. The TFF family is expressed in pancreatic β-cells, whereas the role of TFF2 in pancreatic β-cells has been obscure. In this study, we investigated the mechanism by which TFF2 enhances pancreatic β-cell proliferation. The effects of TFF2 on cell proliferation were evaluated in INS-1 cells, MIN6 cells, and mouse islets using an adenovirus vector containing TFF2 or a recombinant TFF2 peptide. The forced expression of TFF2 led to an increase in bromodeoxyuridine (BrdU) incorporation in both INS-1 cells and islets, without any alteration in insulin secretion. TFF2 significantly increased the mRNA expression of cyclin A2, D1, D2, D3, and E1 in islets. TFF2 peptide increased ERK1/2 phosphorylation and BrdU incorporation in MIN6 cells. A MAPK kinase inhibitor (U0126) abrogated the TFF2 peptide-mediated proliferation of MIN6 cells. A CX-chemokine receptor-4 antagonist also prevented the TFF2 peptide-mediated increase in ERK1/2 phosphorylation and BrdU incorporation in MIN6 cells. These results indicated that TFF2 is involved in β-cell proliferation at least partially via CX-chemokine receptor-4-mediated ERK1/2 phosphorylation, suggesting TFF2 may be a novel target for inducing β-cell proliferation.
Insights
Trefoil factor 2 (TFF2) promotes pancreatic beta-cell proliferation by activating ERK1/2 signaling via CX-chemokine receptor-4. This finding suggests TFF2 as a potential therapeutic target for increasing beta-cell mass in type 2 diabetes.
Area of Science:
- Endocrinology
- Cell Biology
- Molecular Medicine
Background:
- Decreased pancreatic beta-cell mass is a key feature of type 2 diabetes.
- Gastrointestinal incretin peptides are known to promote beta-cell proliferation.
- Trefoil factor 2 (TFF2), a stomach-derived peptide, has roles in cell migration and proliferation, but its function in pancreatic beta-cells was unclear.
Purpose of the Study:
- To investigate the mechanism by which TFF2 enhances pancreatic beta-cell proliferation.
- To explore the potential of TFF2 as a therapeutic target for increasing beta-cell mass.
Main Methods:
- TFF2 was overexpressed using adenovirus vectors or administered as a recombinant peptide in INS-1 cells, MIN6 cells, and mouse islets.
- Cell proliferation was assessed by bromodeoxyuridine (BrdU) incorporation.
- Gene expression of cyclins was analyzed using quantitative PCR.
- ERK1/2 phosphorylation was measured by Western blot.
- Specific inhibitors (U0126 for MAPK kinase, CX-chemokine receptor-4 antagonist) were used to elucidate signaling pathways.
Main Results:
- TFF2 overexpression significantly increased BrdU incorporation in beta-cells, indicating enhanced proliferation, without affecting insulin secretion.
- TFF2 upregulated the expression of key cell cycle regulators, including cyclins A2, D1, D2, D3, and E1.
- TFF2 peptide treatment led to increased ERK1/2 phosphorylation and BrdU incorporation in MIN6 cells.
- Inhibition of MAPK kinase or CX-chemokine receptor-4 abolished TFF2-induced beta-cell proliferation and ERK1/2 activation.
Conclusions:
- TFF2 promotes pancreatic beta-cell proliferation through the CX-chemokine receptor-4-mediated activation of the ERK1/2 signaling pathway.
- TFF2 represents a novel therapeutic target for strategies aimed at increasing beta-cell mass in type 2 diabetes.
- Further research into TFF2's role could lead to new treatments for diabetes.
Related Concept Videos
TGF - β Signaling Pathway
Cell Specific Gene Expression
Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal
PI3K/mTOR/AKT Signaling Pathway
MAPK Signaling Cascades
Mitogens and the Cell Cycle

